Garvey, Edward P.
Viamet Pharmaceuticals (United States)
9 papers on CoChat
Most cited papers
- Verified
The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Plant Pathogen Control
Cited by 173
- Verified
The investigational drug VT-1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme
Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2016) · Antimicrobial Agents and Chemotherapy
Fungal Infections and StudiesAntifungal resistance and susceptibility
Cited by 75
- Verified
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds
Schell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Plant Pathogen Control
Cited by 74
- Verified
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii
Lockhart, S. R., Fothergill, A. W., Iqbal, N., Bolden, C. B., Grossman, N. T., Garvey, E. P., Brand, S. R., Hoekstra, W. J., Schotzinger, R. J., Ottinger, E., et al. (2016) · Antimicrobial Agents and Chemotherapy
Fungal Infections and StudiesAntifungal resistance and susceptibility
Cited by 67
- Verified
In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Plant Pathogen Control
Cited by 52
- Verified
The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis
Garvey, E. P., Sharp, A. D., Warn, P. A., Yates, C. M., & Schotzinger, R. J. (2018) · Journal of Antimicrobial Chemotherapy
Fungal Infections and StudiesAntifungal resistance and susceptibility
Cited by 39
- Verified
VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans
Break, T. J., Desai, J. V., Natarajan, M., Ferre, E. M. N., Henderson, C., Zelazny, A. M., Siebenlist, U., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2018) · Journal of Antimicrobial Chemotherapy
Antifungal resistance and susceptibilityFungal Plant Pathogen Control
Cited by 34
- Verified
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis
Wiederhold, N. P., Najvar, L. K., Garvey, E. P., Brand, S. R., Xu, X., Ottinger, E. A., Alimardanov, A., Cradock, J., Behnke, M., Hoekstra, W. J., et al. (2018) · Antimicrobial Agents and Chemotherapy
Fungal Infections and StudiesAntifungal resistance and susceptibility
Cited by 27
- Verified
Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs
Nielsen, K., Vedula, P., Smith, K. D., Meya, D. B., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Boulware, D. R. (2016) · Medical Mycology
Fungal Infections and StudiesAntifungal resistance and susceptibility
Cited by 24
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free